Scientific Resources

hero-background-image
202608 - Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumour-infiltrating lymphocytes for colorectal cancer drug discovery .png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

17 August 2026

|

4 min read

Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumourinfiltrating lymphocytes for colorectal cancer drug discovery

This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.

Complex Bioassays Bridging Analytics and Clinical Relevance in Biosimilar Development.png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

30 June 2026

|

4 min read

Complex Bioassays: Bridging Analytics and Clinical Relevance in Biosimilar Development

This poster illustrates how complex primary cell-based assays contribute to biosimilar comparability by addressing key mechanisms of action and fulfilling roles central to regulatory expectations integrating biological activity assessment, indication extrapolation and the linkage of analytical data with clinical relevance.

10 years of innovation Celebrating RoukenBio's journey (3).png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

15 May 2026

|

5 min read

Assessing Absence of Effector Function: Binding and Primary Cell-Based Assays for Biosimilar Development

Proving biosimilar comparability requires more than assumed Fc silencing. Even widely used ‘silent’ mutations can retain residual activity, making advanced binding and functional assays essential to accurately characterise Fc properties and meet regulatory expectations.

LocIn A Targeted Integration System for the Efficient Creation of Isogenic Mammalian Cell Lines.png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

17 April 2026

|

4 min read

LocIn: A Targeted Integration System for the Efficient Creation of Isogenic Mammalian Cell Lines

Advances in cell line engineering are transforming how biological systems are studied, enabling greater consistency, control, and reproducibility in experimental design. Targeted integration approaches play a key role in overcoming variability introduced by traditional, random integration methods.

Join our community of curious minds on LinkedIn

🗓️ Stay informed with our monthly scientific newsletter, published on LinkedIn on the last Wednesday of each month.

These editions bring you the latest in drug development breakthroughs, industry trends, and expert insights from the brilliant minds at RoukenBio.

Subscribe today on LinkedIn

Propel drug discovery breakthroughs with RoukenBio

Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.

RoukenBio - Capabilities brochure.pngcta-image